216 related articles for article (PubMed ID: 29963728)
21. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
22. The Role of FBXW7 in Gynecologic Malignancies.
Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
Cells; 2023 May; 12(10):. PubMed ID: 37408248
[TBL] [Abstract][Full Text] [Related]
23.
Close V; Close W; Kugler SJ; Reichenzeller M; Yosifov DY; Bloehdorn J; Pan L; Tausch E; Westhoff MA; Döhner H; Stilgenbauer S; Oswald F; Mertens D
Blood; 2019 Feb; 133(8):830-839. PubMed ID: 30510140
[No Abstract] [Full Text] [Related]
24. In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
Dinoi G; Mariani A; Martinelli E; Ciucci A; Zannoni GF; Weaver AL; Keeney GL; Vasmatzis G; Anastasiadis PZ; Fanfani F; Scambia G; Gallo D
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1647-1658. PubMed ID: 33754208
[TBL] [Abstract][Full Text] [Related]
25. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
26. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
[TBL] [Abstract][Full Text] [Related]
27. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
[TBL] [Abstract][Full Text] [Related]
28. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
[TBL] [Abstract][Full Text] [Related]
29.
Liu F; Zou Y; Wang F; Yang B; Zhang Z; Luo Y; Liang M; Zhou J; Huang O
Genet Test Mol Biomarkers; 2019 Jun; 23(6):409-417. PubMed ID: 31161818
[No Abstract] [Full Text] [Related]
30. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
31. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
[TBL] [Abstract][Full Text] [Related]
32. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
[TBL] [Abstract][Full Text] [Related]
33. Degradation of the endoplasmic reticulum-anchored transcription factor MyRF by the ubiquitin ligase SCF
Nakayama S; Yumimoto K; Kawamura A; Nakayama KI
J Biol Chem; 2018 Apr; 293(15):5705-5714. PubMed ID: 29472293
[TBL] [Abstract][Full Text] [Related]
34. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
[TBL] [Abstract][Full Text] [Related]
35. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
36. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.
Ono K; Hayashi H; Tateno M; Tanaka R; Suzuki R; Maruyama Y; Miyagi Y; Furuya M
Int J Clin Exp Pathol; 2014; 7(11):7979-88. PubMed ID: 25550841
[TBL] [Abstract][Full Text] [Related]
37. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
[TBL] [Abstract][Full Text] [Related]
38. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells.
Guo Z; Zhou Y; Evers BM; Wang Q
Biochem Biophys Res Commun; 2012 Feb; 418(2):426-32. PubMed ID: 22285861
[TBL] [Abstract][Full Text] [Related]
39. CRL2
Motomura S; Yumimoto K; Tomonaga T; Nakayama KI
Oncogene; 2024 Jun; 43(25):1917-1929. PubMed ID: 38698266
[TBL] [Abstract][Full Text] [Related]
40. Recurrent mutations in tumor suppressor
Zhong Z; Virshup DM
Sci Adv; 2024 Apr; 10(14):eadk1031. PubMed ID: 38569029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
